SCHEMBL29377204

SCHEMBL29377204

OB(O)c1ccc(N2CCCC2)nc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UBE2T Q9NPD8 1/20 0.51
MAPT P10636 2/20 0.47
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.46
ALOX12 P18054 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
CNR2 P34972 9/20 0.44
CNR1 P21554 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.41
AOC3 Q16853 2/20 0.40
KDM4E B2RXH2 2/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.40
HPGD P15428 1/20 0.40
ALOX15 P16050 1/20 0.40
HSD17B10 Q99714 1/20 0.40
KCNQ3 O43525 1/20 0.39
KCNQ2 O43526 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL676085 1.00 UBE2T (0.51) UBE2TMAPTALDH1A1LMNAALOX12
SCHEMBL29951844 0.98 UBE2T (0.50) UBE2TMAPTALDH1A1LMNAALOX12
SCHEMBL29951531 0.98 UBE2T (0.50) UBE2TMAPTALDH1A1LMNAALOX12
SCHEMBL3941056 0.98 UBE2T (0.50) UBE2TMAPTALDH1A1LMNAALOX12
SCHEMBL3643028 0.89 UBE2T (0.43) UBE2TMAPTALDH1A1LMNAALOX12
SCHEMBL14167546 0.86 CNR2 (0.53) MAPTALDH1A1LMNACNR2SMN1; SMN2
SCHEMBL14167530 0.86 HTR3A (0.43) UBE2TALDH1A1SMN1; SMN2KDM4EKMT2A
SCHEMBL26100489 0.86 CHRNB2 (0.44) UBE2T
SCHEMBL24092779 0.86 UBE2T (0.49) UBE2TMAPTALDH1A1LMNAALOX12
SCHEMBL9147 0.84 ALDH1A1 (0.54) MAPTALDH1A1LMNACNR2SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087909-A1 COMPOUNDS FOR USE AS NEUROPROTECTIVE AGENTS AND/OR IN INHIBITING FORMATION OF ALPHA-SYNUCLEIN AGGREGATES AC IMMUNE SA (CH) 2026-04-30 WO disclosed
EP-4713093-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES AC Immune SA (CH) 2026-03-25 EP disclosed
CN-116472047-B Arylamine derivative, preparation method and medical application thereof 中国医药研究开发中心有限公司 2025-06-17 CN disclosed
WO-2024236059-A1 NOVEL COMPOUNDS FOR THE TREATMENT OF DISEASE ASSOCIATED WITH ALPHA-SYNUCLEIN AGGREGATES AC IMMUNE SA (CH) 2024-11-21 WO disclosed
EP-4423081-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF The Children's Medical Center Corporation (US) 2024-09-04 EP disclosed
EP-4359389-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2024-05-01 EP disclosed
CN-117321048-A Compounds and compositions for the treatment of diseases associated with STING activity 艾福姆德尤股份有限公司 2023-12-29 CN disclosed
EP-4263531-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM Due, Inc. (US) 2023-10-25 EP disclosed
CN-116472047-A Arylamine derivative, preparation method and medical application thereof 中国医药研究开发中心有限公司 2023-07-21 CN disclosed
WO-2023086220-A2 PAPD5 INHIBITORS AND METHODS OF USE THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2023-05-19 WO disclosed
WO-2022271677-A1 DIACYLGLYERCOL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2022-12-29 WO disclosed
US-20220340893-A1 BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES NUEVOLUTION A/S (DK) 2022-10-27 US disclosed
WO-2022133098-A2 COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY IFM DUE, INC. (US) 2022-06-23 WO disclosed
CN-110177785-B Dihydroisoquinoline compound 苏州爱科百发生物医药技术有限公司 2022-02-08 CN disclosed